In what scenario would you consider dual IO and TKI therapy in advanced stage melanoma?  

Triplet therapy with the combination of vemurafenib, cobimetinib, and atezolizumab provides a new treatment option for patients with advanced BRAF-mutated melanoma. However, given the lack of survival benefit thus far and increased toxicity, I currently do not routinely employ this as frontline ther...